NCT07325682Enrolling by invitation
Diagnostic Evaluation of Viral Persistence in Cervical Cancer
Personalized, Scientifically Based Technologies in the Diagnosis and Treatment of SARS-CoV-2 as a Possible Cervical Cancer Risk Factor
Source: ClinicalTrials.gov · Last updated 8 Oct 2026
Brief summary (registry, in English)
This study aims to evaluate the diagnostic value of an electroacupuncture-based method for detecting viral persistence (human papillomavirus and SARS-CoV-2) in patients with cervical cancer. The study investigates whether persistent viral signatures can be identified through measurable electrodiagnostic responses at acupuncture points associated with organ systems affected by chronic viral infection. The goal is to assess the feasibility, reproducibility, and potential clinical relevance of this diagnostic approach in oncology patients.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 9 Dec 2025
- Start date
- 30 Apr 2025
- Primary completion date
- 30 Jun 2030
- Lead sponsor
- Oncology Center,Ministry Of Heath,Uzbekistan
- Diseases
- Cervical cancer
- NCT number
- NCT07325682
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 30 Apr 2025 to the primary completion date, 30 Jun 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Severe cardiovascular or pulmonary disease
- Severe mental illness or inability to provide informed consent
Lab values
- Poor renal function (elevated creatinine)
- Significant liver dysfunction (elevated bilirubin or liver enzymes)
Other
- Pregnancy or breastfeeding
- Known non-compliance or substance abuse
Who the study is looking for
- Histologically confirmed cervical cancer (FIGO stage IIIA-IVA)
- Age ≥21 years
- ECOG performance status adequate for diagnostic procedures
- Adequate organ function
- Ability to provide informed consent
Age in the registry: 21 years to 70 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Regional Branch of the National Oncology and Radiology Center Coordinator of this site? Confirm its status | Tashkent | Uzbekistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.